

## P&G Hygiene and Healthcare

Estimate changes	↔
TP change	↓
Rating change	↔

Bloomberg	PG IN
Equity Shares (m)	32
M.Cap.(INRb)/(USDb)	381.9 / 4.2
52-Week Range (INR)	14824 / 11612
1, 6, 12 Rel. Per (%)	-6/-17/-27
12M Avg Val (INR M)	141

### Financials & valuations (INR b)

Y/E June	FY26E	FY27E	FY28E
Sales	43.8	47.2	50.7
Sales Gr. (%)	29.9	7.8	7.3
EBITDA	11.8	12.9	14.1
Margin (%)	26.9	27.3	27.8
Adj. PAT	8.8	9.7	10.6
Adj. EPS (INR)	270.1	298.5	326.0
EPS Gr. (%)	37.9	10.5	9.2
BV/Sh.(INR)	281.1	340.9	406.2
<b>Ratios</b>			
RoE (%)	106.4	96.1	87.4
RoCE (%)	120.3	107.2	96.6
<b>Valuations</b>			
P/E (x)	43.6	39.5	36.1
P/BV (x)	41.9	34.6	29.0
EV/EBITDA (x)	32.0	29.0	26.4
Div. Yield (%)	1.8	2.0	2.2

### Shareholding pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	70.6	70.6	70.6
DII	16.0	16.1	15.4
FII	1.1	1.1	1.4
Others	12.3	12.2	12.6

FII Includes depository receipts

**CMP: INR11,766**    **TP: INR13,000 (+10%)**    **Neutral**

### Muted revenue growth continues; beat on margins

- P&G Hygiene and Healthcare's (PGHH) 3QFY26 revenue growth was below our expectations, but was a beat on profitability. PGHH margins have been highly volatile, and such anomalies have been observed in the past quarters as well. Revenue grew 1% YoY to INR12.6b (below) in 3QFY26. The revenue growth trajectory has been flattish over four consecutive quarters now.
- Gross margin expanded 180bp YoY and 530bp QoQ to 66.6% (beat), reflecting the usual volatility between quarters. Employee costs declined 7% YoY, and A&P was down 8% YoY, while other expenses rose 8% YoY. EBITDA grew 8% YoY to INR4b (beat), as EBITDA margin expanded 210bp YoY and 710bp QoQ to 31.8% (beat) on account of lower COGS and operating costs.
- PGHH exhibits significant volatility on a quarterly basis, but its annual performance remains stable. We model a 27-27.8% EBITDA margin during FY26-28E.
- We model Revenue/EBITDA/PAT CAGR of 8%/9%/10% over FY26-28E. Given the volatility in margins, we find other consumer names relatively better than PGHH for growth at the valuation it offers. **We reiterate Neutral with a revised TP of INR13,000 (based on 40x Dec'27E EPS).**

### Flat revenue YoY; strong GM expansion aids profitability

- **Flattish revenue trajectory continues:** PGHH registered 1% YoY revenue growth to INR12.6b (est. INR13b). Revenue growth continues to remain weak, as seen over the last few quarters.
- **Beat on margin:** Gross margin expanded 180bp YoY and 530bp QoQ to 66.6% (est. 63.5%). GM volatility between quarters continues to remain high. Employee costs declined 7% YoY, and A&P dipped 8% YoY, while other expenses rose 8% YoY. EBITDA margin expanded 210bp YoY and 710bp QoQ to 31.8% (est. 28.5%).
- **Strong margins aid profitability:** EBITDA grew 8% YoY to INR4b (est. INR3.7b). PBT grew 10% YoY and Adj. PAT rose 12% YoY to INR3b. (est. INR2.8b).

### Valuation and view

- We broadly retain our EPS estimates for FY26-28.
- Two factors make PGHH an attractive long-term core holding: 1) high growth potential for the feminine hygiene segment (65-68% mix of FY24 sales), coupled with the potential for market share gains and strategic initiatives, including the strengthening of its competitive advantages; and 2) the potential to sustain high operating margins from the long-term premiumization trend in the feminine hygiene segment.
- With a portfolio of essentials and healthcare, PGHH remains focused on product innovation-led customer acquisition. While the penetration play will continue, it is expected to proceed at a stable pace despite the high scope of user additions. Further, we do not see any medium-term upside trigger.
- We model Revenue/EBITDA/PAT CAGR of 8%/9%/10% over FY26-28E. Given the volatility in margins, we find other consumer names relatively better than PGHH for growth at the valuation it offers. **We reiterate Neutral with a revised TP of INR13,000 (based on 40x Dec'27E EPS).**

**Naveen Trivedi – Research Analyst** (Naveen.Trivedi@MotilalOswal.com)

**Research Analyst: Amey Tiwari** (Amey.Tiwari@MotilalOswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)


Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on [www.motilaloswal.com](http://www.motilaloswal.com)/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.


**Standalone - Quarterly Earnings**

Y/E June	(INR m)											
	1Q	2Q	3Q	1Q	2Q	3Q	4QE	FY25*	FY26E	FY26E	3QE	Var.
<b>Net Sales</b>	<b>11,352</b>	<b>12,476</b>	<b>9,916</b>	<b>9,370</b>	<b>11,502</b>	<b>12,619</b>	<b>10,334</b>	<b>33,744</b>	<b>43,825</b>	<b>12,975</b>	<b>-2.7%</b>	
YoY Change (%)	-0.3	10.1	-1.1	0.6	1.3	1.1	4.2	-19.8	29.9	4.0		
<b>Gross profit</b>	<b>7,139</b>	<b>8,085</b>	<b>5,969</b>	<b>5,959</b>	<b>7,050</b>	<b>8,399</b>	<b>6,290</b>	<b>21,193</b>	<b>27,697</b>	<b>8,239</b>	<b>1.9%</b>	
Margin (%)	62.9	64.8	60.2	63.6	61.3	66.6	60.9	62.8	63.2	63.5		
<b>EBITDA</b>	<b>2,905</b>	<b>3,709</b>	<b>2,097</b>	<b>2,662</b>	<b>2,848</b>	<b>4,018</b>	<b>2,240</b>	<b>8,711</b>	<b>11,767</b>	<b>3,698</b>	<b>8.7%</b>	
Growth	2.0	19.8	-18.5	102.7	-2.0	8.3	6.8	-11.4	35.1	-0.3		
Margins (%)	25.6	29.7	21.1	28.4	24.8	31.8	21.7	25.8	26.9	28.5		
Depreciation	117	99	104	91	93	95	108	319	386	98		
Interest	19	66	58	1	36	27	72	143	135	40		
Other Income	85	97	191	77	99	124	189	373	489	125		
<b>PBT</b>	<b>2,854</b>	<b>3,641</b>	<b>2,127</b>	<b>2,647</b>	<b>2,818</b>	<b>4,020</b>	<b>2,249</b>	<b>8,622</b>	<b>11,735</b>	<b>3,685</b>	<b>9.1%</b>	
<b>PBT after EO expense</b>	<b>2,854</b>	<b>3,641</b>	<b>2,127</b>	<b>2,647</b>	<b>2,818</b>	<b>4,020</b>	<b>2,249</b>	<b>8,622</b>	<b>11,735</b>	<b>3,685</b>	<b>9.1%</b>	
Tax	735	955	566	726	719	1,006	506	2,256	2,957	929		
Rate (%)	25.7	26.2	26.6	27.4	25.5	25.0	22.5	26.2	25.2	25.2		
<b>Adj PAT</b>	<b>2,119</b>	<b>2,686</b>	<b>1,561</b>	<b>1,921</b>	<b>2,099</b>	<b>3,015</b>	<b>1,744</b>	<b>6,366</b>	<b>8,777</b>	<b>2,756</b>	<b>9.4%</b>	
YoY Change (%)	0.6	17.3	-15.8	111.4	-1.0	12.2	11.7	-11.1	37.9	2.6		
Margins (%)	18.7	21.5	15.7	20.5	18.2	23.9	16.9	18.9	20.0	21.2		


E: MOFSL Estimates; \*FY25 has only 9M as the company changed its year-end from Jun to Mar

**Key exhibits**
**Exhibit 1: Net sales grew 1% YoY to INR12.6b**



Source: Company, MOFSL

**Exhibit 2: EBITDA up 8.3% YoY to INR4b**


Source: Company, MOFSL


**Exhibit 3: Gross margin expanded 180bp YoY to 66.6%**


Source: Company, MOFSL

**Exhibit 4: EBITDA margin expanded 210bp YoY to 31.8%**


Source: Company, MOFSL

Exhibit 5: As a percentage of sales, ad spending contracted 120bp, staff costs dipped 40bp, while other expenses rose 120bp YoY



Source: Company, MOFSL

\*The December quarter is now 3QFY26, as the company changed the end-year from Jun to Mar

## Valuation and view


- We broadly retain our EPS estimates for FY26-28.
- Two factors make PGHH an attractive long-term core holding: 1) high growth potential for the feminine hygiene segment (65-68% mix of FY24 sales), coupled with the potential for market share gains and strategic initiatives, including the strengthening of its competitive advantages; and 2) the potential to sustain high operating margins from the long-term premiumization trend in the feminine hygiene segment.
- With a portfolio of essentials and healthcare, PGHH remains focused on product innovation-led customer acquisition. While the penetration play will continue, it is expected to proceed at a stable pace despite the high scope of user additions. Further, we do not see any medium-term upside trigger.
- We model Revenue/EBITDA/PAT CAGR of 8%/9%/10% over FY26-28E. Given the volatility in margins, we find other consumer names relatively better than PGHH for growth at the valuation it offers. **We reiterate Neutral with a revised TP of INR13,000 (based on 40x Dec'27E EPS).**

Exhibit 6: We largely maintain our EPS estimates for FY26E-28E

INR m	New			Old			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Net Sales	43,825	47,226	50,676	44,756	48,171	51,689	-2.1%	-2.0%	-2.0%
EBITDA	11,767	12,869	14,063	11,681	12,789	14,240	0.7%	0.6%	-1.2%
Adjusted PAT	8,777	9,702	10,594	8,713	9,643	10,727	0.7%	0.6%	-1.2%


Source: MOFSL

Exhibit 7: PGHH's P/E (x)



Source: Bloomberg, MOFSL

Exhibit 8: Consumer sector P/E (x)



Source: Bloomberg, MOFSL

## Financials and valuations

Standalone - Income Statement							(INR m)		
Y/E June	FY20	FY21	FY22	FY23	FY24	FY25 (9M)	FY26E	FY27E	FY28E
<b>Total Income from Operations</b>	<b>30,020</b>	<b>35,741</b>	<b>37,998</b>	<b>39,123</b>	<b>42,057</b>	<b>33,744</b>	<b>43,825</b>	<b>47,226</b>	<b>50,676</b>
Change (%)	1.9	19.1	6.3	3.0	7.5	-19.8	29.9	7.8	7.3
Raw Materials	11,068	11,593	14,582	16,575	16,142	12,551	16,127	17,261	18,395
% of Sales	36.9	32.4	38.4	42.4	38.4	37.2	36.8	36.6	36.3
Employees Cost	1,733	2,017	2,143	2,058	2,456	1,761	2,147	2,314	2,736
% of Sales	5.8	5.6	5.6	5.3	5.8	5.2	4.9	4.9	5.4
Other Expenses	11,003	15,160	12,974	11,805	13,626	10,722	13,783	14,782	15,481
% of Sales	36.7	42.4	34.1	30.2	32.4	31.8	31.5	31.3	30.6
<b>Total Expenditure</b>	<b>23,804</b>	<b>28,770</b>	<b>29,699</b>	<b>30,437</b>	<b>32,224</b>	<b>25,034</b>	<b>32,058</b>	<b>34,357</b>	<b>36,613</b>
% of Sales	79.3	80.5	78.2	77.8	76.6	74.2	73.2	72.8	72.3
<b>EBITDA</b>	<b>6,216</b>	<b>6,972</b>	<b>8,299</b>	<b>8,686</b>	<b>9,833</b>	<b>8,711</b>	<b>11,767</b>	<b>12,869</b>	<b>14,063</b>
Margin (%)	20.7	19.5	21.8	22.2	23.4	25.8	26.9	27.3	27.8
Depreciation	479	477	529	584	565	319	386	392	404
<b>EBIT</b>	<b>5,738</b>	<b>6,495</b>	<b>7,770</b>	<b>8,103</b>	<b>9,268</b>	<b>8,391</b>	<b>11,381</b>	<b>12,477</b>	<b>13,658</b>
Int. and Finance Charges	61	61	112	114	268	143	135	139	143
Other Income	441	394	243	406	523	373	489	633	647
<b>PBT bef. EO Exp.</b>	<b>6,118</b>	<b>6,828</b>	<b>7,901</b>	<b>8,395</b>	<b>9,522</b>	<b>8,622</b>	<b>11,735</b>	<b>12,971</b>	<b>14,163</b>
EO Items	-105	1,450	-101	571	-441	0	0	0	0
<b>PBT after EO Exp.</b>	<b>6,013</b>	<b>8,277</b>	<b>7,800</b>	<b>8,966</b>	<b>9,082</b>	<b>8,622</b>	<b>11,735</b>	<b>12,971</b>	<b>14,163</b>
Total Tax	1,642	1,759	2,042	2,184	2,674	2,256	2,957	3,269	3,569
Tax Rate (%)	27.3	21.3	26.2	24.4	29.4	26.2	25.2	25.2	25.2
<b>Reported PAT</b>	<b>4,371</b>	<b>6,518</b>	<b>5,757</b>	<b>6,781</b>	<b>6,718</b>	<b>6,366</b>	<b>8,777</b>	<b>9,702</b>	<b>10,594</b>
<b>Adjusted PAT</b>	<b>4,476</b>	<b>5,068</b>	<b>5,858</b>	<b>6,210</b>	<b>7,159</b>	<b>6,366</b>	<b>8,777</b>	<b>9,702</b>	<b>10,594</b>
Change (%)	6.8	13.2	15.6	6.0	15.3	-11.1	37.9	10.5	9.2
Margin (%)	14.9	14.2	15.4	15.9	17.0	18.9	20.0	20.5	20.9

Standalone - Balance Sheet							(INR m)		
Y/E June	FY20	FY21	FY22	FY23	FY24	FY25 (9M)	FY26E	FY27E	FY28E
Equity Share Capital	325	325	325	325	325	325	325	325	325
Total Reserves	11,254	6,818	7,051	9,136	7,424	7,045	8,801	10,741	12,860
<b>Net Worth</b>	<b>11,579</b>	<b>7,143</b>	<b>7,376</b>	<b>9,460</b>	<b>7,749</b>	<b>7,370</b>	<b>9,125</b>	<b>11,066</b>	<b>13,185</b>
Deferred Tax Liabilities	-296	-380	-519	-655	-749	-824	-907	-997	-1,097
Total Loans	15	35	19	8	0	0	0	0	0
<b>Capital Employed</b>	<b>11,298</b>	<b>6,797</b>	<b>6,876</b>	<b>8,813</b>	<b>7,000</b>	<b>6,546</b>	<b>8,219</b>	<b>10,069</b>	<b>12,088</b>
Gross Block	4,495	4,719	5,012	5,582	5,838	6,036	6,236	6,436	6,636
Less: Accum. Deprn.	2,430	2,881	3,376	3,881	4,446	4,722	5,152	5,544	5,948
<b>Net Fixed Assets</b>	<b>2,065</b>	<b>1,838</b>	<b>1,637</b>	<b>1,700</b>	<b>1,392</b>	<b>1,314</b>	<b>1,084</b>	<b>892</b>	<b>688</b>
Goodwill on Consolidation	0	0	0	0	0	0	0	0	0
Capital WIP	222	376	439	228	278	407	200	200	200
<b>Total Investments</b>	<b>0</b>								
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>15,702</b>	<b>13,733</b>	<b>14,231</b>	<b>18,790</b>	<b>16,168</b>	<b>15,002</b>	<b>16,363</b>	<b>19,179</b>	<b>22,206</b>
Inventory	2,051	2,493	2,340	2,198	2,256	2,214	2,641	2,846	3,054
Account Receivables	1,663	1,424	1,921	2,163	2,408	3,041	2,641	2,846	3,054
Cash and Bank Balance	9,025	6,602	6,393	9,780	5,882	4,807	6,253	8,641	11,232
Loans and Advances	2,963	3,214	3,578	4,649	5,622	4,940	4,827	4,845	4,865
<b>Curr. Liability &amp; Prov.</b>	<b>6,691</b>	<b>9,150</b>	<b>9,431</b>	<b>11,905</b>	<b>10,837</b>	<b>10,177</b>	<b>9,428</b>	<b>10,202</b>	<b>11,006</b>
Account Payables	5,313	7,541	7,798	9,711	8,517	8,094	7,279	7,838	8,406
Other Current Liabilities	587	731	710	1,036	1,185	787	865	952	1,047
Provisions	790	878	923	1,158	1,136	1,296	1,283	1,412	1,553
<b>Net Current Assets</b>	<b>9,011</b>	<b>4,583</b>	<b>4,801</b>	<b>6,885</b>	<b>5,331</b>	<b>4,825</b>	<b>6,935</b>	<b>8,977</b>	<b>11,200</b>
<b>Appl. of Funds</b>	<b>11,298</b>	<b>6,797</b>	<b>6,876</b>	<b>8,813</b>	<b>7,000</b>	<b>6,546</b>	<b>8,219</b>	<b>10,069</b>	<b>12,088</b>

E: MOFSL Estimates

## Financials and valuations

### Ratios

Y/E June	FY20	FY21	FY22	FY23	FY24	FY25 (9M)	FY26E	FY27E	FY28E
<b>Basic (INR)</b>									
EPS	137.7	156.1	180.5	191.3	220.3	195.9	270.1	298.5	326.0
Cash EPS	152.7	170.8	196.8	209.3	237.9	206.0	282.3	311.0	338.8
BV/Share	356.7	220.0	227.2	291.4	238.7	227.0	281.1	340.9	406.2
DPS	105	315	160	185	255	157	216	239	261
Payout (%)	78.1	202.0	88.8	96.8	123.4	80.0	80.0	80.0	80.0
<b>Valuation (x)</b>									
P/E	85.5	75.5	65.3	61.6	53.5	60.2	43.6	39.5	36.1
Cash P/E	77.2	69.0	59.9	56.3	49.5	57.2	41.7	37.9	34.8
P/BV	33.0	53.5	51.9	40.4	49.4	51.9	41.9	34.6	29.0
EV/Sales	12.4	10.5	9.9	9.5	9.0	11.2	8.6	7.9	7.3
EV/EBITDA	60.1	53.9	45.3	42.9	38.3	43.4	32.0	29.0	26.4
Dividend Yield (%)	0.9	2.7	1.4	1.6	2.2	1.3	1.8	2.0	2.2
FCF per share	130.5	256.2	161.2	240.7	127.9	165.9	251.2	300.3	328.5
<b>Return Ratios (%)</b>									
RoE	43.3	54.1	80.7	73.8	83.2	84.2	106.4	96.1	87.4
RoCE	44.9	60.0	86.5	82.0	87.4	95.5	120.3	107.2	96.6
<b>Working Capital Ratios</b>									
Asset Turnover (x)	2.7	5.3	5.5	4.4	6.0	5.2	5.3	4.7	4.2
Inventory (Days)	25	23	23	21	22	22	22	22	22
Debtor (Days)	21	16	16	19	22	22	22	22	22
Creditor (Days)	66	66	74	82	60	60	60	60	60
Net WCC	-20	-27	-34	-41	-16	-16	-16	-16	-16
<b>Growth (%)</b>									
Sales	1.9	19.1	6.3	3.0	7.5	-19.8	29.9	7.8	7.3
EBITDA	2.0	12.2	19.0	4.7	13.2	-11.4	35.1	9.4	9.3
PAT	6.8	13.2	15.6	6.0	15.3	-11.1	37.9	10.5	9.2
<b>Leverage Ratio (x)</b>									
Current Ratio	2.3	1.5	1.5	1.6	1.5	1.5	1.7	1.9	2.0
Interest Cover Ratio	94.5	106.3	69.4	71.2	34.6	58.7	84.3	89.7	95.4
Debt/Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

### Standalone - Cash Flow Statement

(**INR m**)

Y/E June	FY20	FY21	FY22	FY23	FY24	FY25 (9M)	FY26E	FY27E	FY28E
<b>PBT</b>									
PBT	5,939	8,699	7,901	8,395	9,392	8,622	11,735	12,971	14,163
Depreciation	479	477	529	584	565	319	386	392	404
Net interest expense	-266	-250	-154	-237	-367	-136	-354	-494	-504
Others	203	139	115	67	97	130	0	0	0
(Inc)/Dec in WC	-179	2,101	-166	1,745	-2,321	-572	-664	346	368
Taxes	-1,435	-2,534	-2,494	-2,295	-2,782	-2,431	-2,957	-3,269	-3,569
<b>CF from Operations</b>	<b>4,741</b>	<b>8,631</b>	<b>5,731</b>	<b>8,258</b>	<b>4,584</b>	<b>5,932</b>	<b>8,146</b>	<b>9,946</b>	<b>10,862</b>
<b>CF from Operating incl EO</b>	<b>4,741</b>	<b>8,631</b>	<b>5,731</b>	<b>8,258</b>	<b>4,584</b>	<b>5,932</b>	<b>8,146</b>	<b>9,946</b>	<b>10,862</b>
(Inc)/Dec in FA	-503	-315	-497	-444	-433	-546	7	-200	-200
<b>Free Cash Flow</b>	<b>4,237</b>	<b>8,317</b>	<b>5,234</b>	<b>7,814</b>	<b>4,151</b>	<b>5,386</b>	<b>8,153</b>	<b>9,746</b>	<b>10,662</b>
Others	1,265	325	246	344	568	202	533	633	647
<b>CF from Investments</b>	<b>783</b>	<b>11</b>	<b>-251</b>	<b>-100</b>	<b>136</b>	<b>-344</b>	<b>540</b>	<b>433</b>	<b>447</b>
Dividend Paid	-1,878	-11,037	-5,681	-4,707	-8,602	-6,655	-7,022	-7,762	-8,475
Interest Paid	-9	-10	-25	-51	-5	0	-135	-139	-143
Others	-16	-18	16	-12	-10	0	-82	-91	-100
<b>CF from Fin. Activity</b>	<b>-1,903</b>	<b>-11,064</b>	<b>-5,689</b>	<b>-4,770</b>	<b>-8,618</b>	<b>-6,662</b>	<b>-7,239</b>	<b>-7,991</b>	<b>-8,718</b>
<b>Inc/Dec of Cash</b>	<b>3,621</b>	<b>-2,423</b>	<b>-210</b>	<b>3,387</b>	<b>-3,898</b>	<b>-1,075</b>	<b>1,446</b>	<b>2,388</b>	<b>2,591</b>
Opening Balance	5,405	9,025	6,603	6,393	9,780	5,882	4,807	6,253	8,641
<b>Closing Balance</b>	<b>9,025</b>	<b>6,603</b>	<b>6,393</b>	<b>9,780</b>	<b>5,882</b>	<b>4,807</b>	<b>6,253</b>	<b>8,641</b>	<b>11,232</b>

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022- 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH00000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.